Snowball logo
logo
6886

Beijing Sun Novo Pharmaceutical Research Co Ltd

688621 • SHG
¥72.75-¥2.51  (3.34%)
Estimate
P/E
158.2
EPS
0.46
Beta
-0.105
Growth
Revenue, YoY
-36.28%
Net income, YoY
-144.92%
FCF, YoY
-76.75%
Dividends
Dividend yield
0.26%
Annual payout
¥0.19
Next ex. div date
June 29, 27
Payout
73.79%
Dividend growth streak
1 year
Div.rating
About the company
Ticker
688621
ISIN
CNE100005139
Country
China
Sector (GICS)
Healthcare
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; oncology, metabolic diseases, respiratory tract drug delivery and topical preparation platforms; polypeptide and other drug molecular design and development platform; genotoxic impurity detection platform; technology platform for slow and controlled release preparations; drug synthesis platform; and synthesis technology platform. It also offers SMO, clinical quality management, data management and statistical analysis, project management, test center, clinical research center, clinical trials, TMFDocument management, quality control, Medical Writing, medical monitoring, and pharmacovigilance services; and registration-related services for chemical drugs, biological products, and medical device products. In addition, the company operates a quantitative pharmacology platform that uses technology in pharmacokinetics, pharmacodynamics, body function, disease mechanism and test process, and other information for quantitative research; and mass spectrometry, immunological analysis, cell biology, and molecular biology platforms that provide biological analysis services for large and small molecular drugs, as well as operates as a Contract Research Organization for Professional Peptide Drug Research and Development. The company offers clinical research technology services to pharmaceutical companies and new drug research institutions. Beijing Sun-Novo Pharmaceutical Research Co., Ltd. was founded in 2009 and is based in Beijing, China.

Frequently asked questions

What sector does Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) operate in?

Beijing Sun Novo Pharmaceutical Research Co Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) current stock price?

As of the latest data, Beijing Sun Novo Pharmaceutical Research Co Ltd stock price is CN¥72.75, with a previous close of CN¥75.26. Beijing Sun Novo Pharmaceutical Research Co Ltd lost -CN¥2.51 in the last trading session, representing a -3.34% loss.

What is Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) current market capitalization?

Beijing Sun Novo Pharmaceutical Research Co Ltd market cap is approximately 8.15 billion.

What is Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) Earnings Per Share (EPS)?

The trailing EPS is CN¥0.46.

What is Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) Price-to-Earnings (P/E) ratio?

Beijing Sun Novo Pharmaceutical Research Co Ltd current P/E ratio is 158.15.

Does Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) pay dividends?

Yes. Beijing Sun Novo Pharmaceutical Research Co Ltd pays annual dividends with an annualized yield of 0.26% and an estimated annual payout of CN¥0.19 per share.

When is the next ex-dividend date for Beijing Sun Novo Pharmaceutical Research Co Ltd (688621)?

The next ex-dividend date is scheduled for June 29, 2027.

What is Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) beta (volatility) score?

Beijing Sun Novo Pharmaceutical Research Co Ltd has a beta of -0.105, indicating lower volatility than the overall market.